Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease | Zendy

Edward Gane | Zendy; Fred Poordad | Zendy; Neddie Zadeikis | Zendy; Joaquin Valdes | Zendy; Chih-Wei Lin | Zendy; Wei Liu | Zendy; Armen Asatryan | Zendy; Stanley Wang | Zendy; Catherine Stedman | Zendy; Susan Greenbloom | Zendy; Tuan Nguyen | Zendy; Magdy Elkhashab | Zendy; MarcusAlexander Wörns | Zendy; Albert Tran | Zendy; Jean-Pierre Mulkay | Zendy; Carolyn M. Setze | Zendy; Yao Yu | Zendy; Edward Tam | Zendy; Ariel Porcalla | Zendy; Federico Mensa | Zendy

Open Access

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

Author(s) -

Edward Gane,

Fred Poordad,

Neddie Zadeikis,

Joaquin Valdes,

Chih-Wei Lin,

Wei Liu,

Armen Asatryan,

Stanley Wang,

Catherine Stedman,

Susan Greenbloom,

Tuan Nguyen,

Magdy Elkhashab,

MarcusAlexander Wörns,

Albert Tran,

Jean-Pierre Mulkay,

Carolyn M. Setze,

Yao Yu,

Edward Tam,

Ariel Porcalla,

Federico Mensa

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz022

Subject(s) - genotype , pharmacokinetics , medicine , liver disease , hepatitis c virus , disease , virology , virus , gastroenterology , biology , genetics , gene

Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research